The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a cream to treat atopic dermatitis (AD). Opzelura (ruxolitinib) cream, developed by Incyte International for the treatment of moderate atopic dermatitis (AD), has been recommended for adult patients for whom topical corticosteroids… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Thibaud Portal, Founder… Read More
Global biopharmaceutical company UCB has announced new 12-week efficacy and 18-week safety data from the Phase I/IIa first-in-patient trial for galvokimig, investigating treatment for atopic dermatitis (AD). Galvokimig, a novel multi-specific antibody-based therapeutic, is currently under clinical investigation for adults living with moderate-to severe cases of AD. Read More
The University of Liverpool’s spin-out company, Galytx, has signed an exclusive licensing agreement with dermatology biotech Quodria. Together the companies plan to develop a first-in-class treatment for atopic dermatitis (AD), a form of eczema. Galytx, launched in June 2024, focuses on the development of galectin-3… Read More
The US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ENV-294 targeting atopic dermatitis and other inflammatory conditions. A Phase I clinical trial has since started for ENV-294, with the first patient dosed at the end of October. Read More
South Korean researchers have found that the use of Janus kinase (JAK) inhibitors as a treatment for atopic dermatitis (AD) is not associated with a greater risk of serious adverse events. While several biologic treatment approaches have been proposed in the recent years for the treatment… Read More
A new drug for atopic dermatitis (AD) has demonstrated a positive clinical effect and improvements in various efficacy endpoints after four weeks of treatment. The Phase Ia/IIb study was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and CCR4 surface receptor occupancy of zelnecirnon in eligible… Read More
A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have… Read More
A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal… Read More
